More from the Author

• Teaching Note | HBS Case Collection | 2013

  Rock Health

  Robert Higgins and Ian McKown Cornell

  This is the teaching note associated with HBS Case #813035. The case should enable students to identify emerging challenges, evaluate Rock Health's funding model, debate the effectiveness of its incubation service and assess its long-term viability.

  Keywords: innovation; Incubation; Healthcare Technology; entrepreneurship; Startups; Entrepreneurship; Innovation and Management; Health Care and Treatment; Business Startups; Health Industry; San Francisco; California; United States;

  Citation:

  Higgins, Robert, and Ian McKown Cornell. "Rock Health." Harvard Business School Teaching Note 813-136, June 2013.

  CiteView DetailsPurchase

  Related

• Case | HBS Case Collection | 2012 (Revised from original 2012 version)

  Kyruus: Big Data's Search for the Killer App

  Robert F. Higgins, Penrose O'Donnell and Mehul Bhatt

  Kyruus is used in a course at HBS on Entrepreneurship in Healthcare IT and Services (EHITS). It describes a young company that has built a very large database on physicians. The company has had some early successful pilots with prominent customers, but it is now faced with choices on which markets to pursue. These markets each offer opportunity, but the company must make some decisions. As is often the case in early stage companies, these choices will affect a number of things, including organizational needs and capital requirements.

  Keywords: Entrepreneurship; Information Technology; Business Startups; Boston;

  Citation:

  Higgins, Robert F., Penrose O'Donnell, and Mehul Bhatt. "Kyruus: Big Data's Search for the Killer App." Harvard Business School Case 813-060, December 2012. (Revised from original September 2012 version.)

  CiteView DetailsPurchase

  Related

• Teaching Plan | HBS Case Collection | 2012 (Revised from original 2012 version)

  Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech (TP)

  Robert F. Higgins

  This is the teaching note related to HBS case 808005. In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates into development. However, several questions related to the integration of Aurora into Vertex were still unresolved, the most pressing being Aurora's major collaboration with the Cystic Fibrosis Foundation (CFF). Were venture philanthropy and foundation deals an appropriate funding mechanism for a public company like Vertex?

  Keywords: venture philanthropy; biotechnology; funding philanthropy venture; venture capital; cystic fibrosis; foundations; Pharmaceuticals; Mergers and Acquisitions; For-Profit Firms; Venture Capital; Giving and Philanthropy; Science-Based Business; Nonprofit Organizations; Pharmaceutical Industry; Biotechnology Industry; United States; San Diego;

  Citation:

  Higgins, Robert F. "Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech (TP)." Harvard Business School Teaching Plan 813-021, October 2012. (Revised from original October 2012 version.)

  CiteView DetailsPurchase

  Related